Ab jetzt beobachten - hier schlummert ein Schatz
Seite 13 von 22 Neuester Beitrag: 04.11.24 13:48 | ||||
Eröffnet am: | 05.06.15 17:16 | von: black-moon | Anzahl Beiträge: | 533 |
Neuester Beitrag: | 04.11.24 13:48 | von: elmario1 | Leser gesamt: | 194.287 |
Forum: | Hot-Stocks | Leser heute: | 168 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 10 | 11 | 12 | | 14 | 15 | 16 | ... 22 > |
https://web.tmxmoney.com/...id=7953264662678935&qm_symbol=ATNM:US
Da ich aber von der Pipeline überzeugt bin, hab ich heute verbilligt!
Der Fortschritt anhand der letzten PR's passt ja erstmal.
Der Markt soll sich erstmal beruhigen hier....
Gestern war Schlusskurs 0,45$ bei 119mio Aktien
Nun kommen 43 Mio Aktien über das Offering dazu.
Dann müsste der Aktienkurs, um die MK beizubehalten, bei 0,33$ stehen.
Schlusskurs heute 0,31$
Wenn die Kapitalerhöhung erfolgreich ist und zeitnah gute News folgen, sollte sich der Kurs wieder etwas erholen.
Und der Outlook ist ja fundamental erstmal nach wie vor sehr gut - siehe Investor Presentation von April 2019:
https://d1io3yog0oux5.cloudfront.net/...entation_April+2019+Final.pdf
Schlusskurs 17.04.: 0,45 USD
Eröffnungskurs 18.04.: 0,33 USD
Auch das wird (hoffentlich bald) wieder geschlossen...
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
First analysis demonstrating the single agent activity of Iomab-B in the SIERRA trial - Poster presentation to highlight the rapid reduction in peripheral blasts following Iomab-B administration leading to significantly lower circulating leukemia burden in patients prior to their bone marrow transplant
https://web.tmxmoney.com/...id=5025873883549813&qm_symbol=ATNM:US
NEW YORK, May 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago. The data to be presented at ASCO is a new analysis from the first 25% of patients enrolled in the SIERRA trial highlighting that by day 3 after Iomab-B administration, patients had a 98% median reduction in peripheral blasts and 100% reduction in blasts by day 8. This significant and rapid reduction in blasts occurred with patients receiving only a single therapeutic infusion of Iomab-B and no other pre-transplant conditioning. As a result, patients had significantly lower circulating leukemia burden prior to their BMT or Bone Marrow Transplant with all patients that received a therapeutic infusion of Iomab-B having robust engraftment despite active disease prior to Iomab-B conditioning.
Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
Dr. Tomlinson, said, "Older patients with active, relapsed or refractory AML are an underserved patient population. These patients, particularly those with high blast counts as seen in the SIERRA trial, are not typically considered candidates for transplant, which is a potentially curative treatment for AML, and have a poor prognosis with other therapeutic options. Iomab-B has uniquely demonstrated an ability to effectively condition these patients for transplant with robust engraftment. We hypothesized that this successful engraftment is due to the myeloablation and anti-leukemic effect of Iomab-B, since these patients had a median of 30% bone marrow blasts prior to transplant. Therefore, we are highly encouraged to observe that Iomab-B as a single agent has a significant anti-leukemic effect and rapidly reduces peripheral blasts